EA201991575A1 - Вакцинная композиция против опоясывающего герпеса - Google Patents
Вакцинная композиция против опоясывающего герпесаInfo
- Publication number
- EA201991575A1 EA201991575A1 EA201991575A EA201991575A EA201991575A1 EA 201991575 A1 EA201991575 A1 EA 201991575A1 EA 201991575 A EA201991575 A EA 201991575A EA 201991575 A EA201991575 A EA 201991575A EA 201991575 A1 EA201991575 A1 EA 201991575A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- herpes zoster
- vaccine composition
- against herpes
- composition against
- glycoprotein
- Prior art date
Links
- 208000007514 Herpes zoster Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 201000006082 Chickenpox Diseases 0.000 abstract 1
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 abstract 1
- 206010046980 Varicella Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- YGPZYYDTPXVBRA-RTDBHSBRSA-N [(2r,3s,4r,5r,6s)-2-[[(2r,3r,4r,5s,6r)-3-[[(3r)-3-dodecanoyloxytetradecanoyl]amino]-6-(hydroxymethyl)-5-phosphonooxy-4-[(3r)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-3,6-dihydroxy-5-[[(3r)-3-hydroxytetradecanoyl]amino]oxan-4-yl] (3r)-3-hydr Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)O1 YGPZYYDTPXVBRA-RTDBHSBRSA-N 0.000 abstract 1
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 229940124590 live attenuated vaccine Drugs 0.000 abstract 1
- 229940023012 live-attenuated vaccine Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к вакцинной композиции против опоясывающего герпеса, которая содержит гликопротеин E из вируса ветряной оспы, глюкопиранозильный липидный адъювант и поддающееся метаболизму масло и селективно увеличивает опосредованную клетками иммунную реакцию без наличия недостатков живых ослабленных вакцин, таким образом, имеет высокую безопасность и сильный профилактический эффект против опоясывающего герпеса.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160178793 | 2016-12-26 | ||
| KR1020170176122A KR102034234B1 (ko) | 2016-12-26 | 2017-12-20 | 대상포진 백신 조성물 |
| PCT/KR2017/015155 WO2018124615A1 (ko) | 2016-12-26 | 2017-12-20 | 대상포진 백신 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201991575A1 true EA201991575A1 (ru) | 2019-12-30 |
| EA038864B1 EA038864B1 (ru) | 2021-10-29 |
Family
ID=62913280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991575A EA038864B1 (ru) | 2016-12-26 | 2017-12-20 | Вакцинная композиция против опоясывающего герпеса |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10940198B2 (ru) |
| EP (1) | EP3560512A4 (ru) |
| JP (2) | JP6815521B2 (ru) |
| KR (2) | KR102034234B1 (ru) |
| CN (1) | CN110198736B (ru) |
| AU (1) | AU2017389221B2 (ru) |
| BR (1) | BR112019013284A2 (ru) |
| CA (1) | CA3048608C (ru) |
| CO (1) | CO2019007795A2 (ru) |
| EA (1) | EA038864B1 (ru) |
| IL (1) | IL267643B2 (ru) |
| MA (1) | MA46310B1 (ru) |
| MX (1) | MX2019007288A (ru) |
| MY (1) | MY195766A (ru) |
| PE (1) | PE20191547A1 (ru) |
| PH (1) | PH12019550106A1 (ru) |
| UA (1) | UA124397C2 (ru) |
| WO (1) | WO2018124615A1 (ru) |
| ZA (1) | ZA201904889B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3868399A4 (en) * | 2018-09-27 | 2022-07-20 | Bravovax Co., Ltd. | IMMUNE COMPOSITION, METHOD FOR PREPARATION AND ASSOCIATED APPLICATION |
| CN110237248A (zh) * | 2019-07-01 | 2019-09-17 | 大连民族大学 | 一种带状疱疹疫苗的制备方法 |
| JP2023506441A (ja) * | 2019-12-13 | 2023-02-16 | 遠大賽威信生命科学（南京）有限公司 | 医薬組成物及びその用途 |
| MX2022011159A (es) * | 2020-03-09 | 2022-11-14 | Dynavax Tech Corp | Vacunas contra herpes zoster que comprende un agonista de tlr9. |
| CN111840538A (zh) * | 2020-05-29 | 2020-10-30 | 中山大学 | 一种水痘-带状疱疹病毒亚单位纳米疫苗的制备方法和应用 |
| US20240033346A1 (en) * | 2020-09-11 | 2024-02-01 | Eubiologics Co., Ltd. | Vaccine composition for chickenpox or varicella zoster and method of using same |
| CN116942808B (zh) * | 2023-07-21 | 2024-02-02 | 北京成大天和生物科技有限公司 | 一种重组带状疱疹疫苗组合物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| EP2486938B1 (en) * | 2006-09-26 | 2018-05-09 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| CA2729011A1 (en) * | 2007-07-19 | 2009-01-22 | Novavax, Inc. | Varicella zoster virus-virus like particles (vlps) and antigens |
| CA2764374C (en) * | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| EP2679683A4 (en) * | 2011-02-24 | 2015-07-15 | Mogam Biotech Res Inst | NEW STRAINS OF VARICELLA-ZOSTER VIRUS, VACCINE AGAINST VARICELLA AND HERPES-ZOSTER VIRUS USING THEM |
| JP6054942B2 (ja) * | 2011-04-08 | 2016-12-27 | イミューン デザイン コーポレイション | 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法 |
| US20180296663A1 (en) | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| MX2018014399A (es) * | 2016-06-01 | 2019-06-06 | Infectious Disease Res Inst | Particulas de nanoalumbre que contienen un agente de dimensionamiento. |
| US10874734B2 (en) * | 2016-11-25 | 2020-12-29 | Mogam Institute For Biomedical Research | Varicella zoster virus vaccine |
-
2017
- 2017-12-20 PE PE2019001327A patent/PE20191547A1/es unknown
- 2017-12-20 EA EA201991575A patent/EA038864B1/ru unknown
- 2017-12-20 UA UAA201908518A patent/UA124397C2/uk unknown
- 2017-12-20 MX MX2019007288A patent/MX2019007288A/es unknown
- 2017-12-20 MA MA46310A patent/MA46310B1/fr unknown
- 2017-12-20 JP JP2019534872A patent/JP6815521B2/ja active Active
- 2017-12-20 KR KR1020170176122A patent/KR102034234B1/ko active IP Right Grant
- 2017-12-20 BR BR112019013284A patent/BR112019013284A2/pt unknown
- 2017-12-20 IL IL267643A patent/IL267643B2/en unknown
- 2017-12-20 CN CN201780080915.XA patent/CN110198736B/zh active Active
- 2017-12-20 WO PCT/KR2017/015155 patent/WO2018124615A1/ko active Application Filing
- 2017-12-20 MY MYPI2019003454A patent/MY195766A/en unknown
- 2017-12-20 EP EP17887387.3A patent/EP3560512A4/en active Pending
- 2017-12-20 AU AU2017389221A patent/AU2017389221B2/en active Active
- 2017-12-20 US US16/473,393 patent/US10940198B2/en active Active
- 2017-12-20 CA CA3048608A patent/CA3048608C/en active Active
-
2019
- 2019-06-17 PH PH12019550106A patent/PH12019550106A1/en unknown
- 2019-07-19 CO CONC2019/0007795A patent/CO2019007795A2/es unknown
- 2019-07-25 ZA ZA2019/04889A patent/ZA201904889B/en unknown
- 2019-10-10 KR KR1020190125559A patent/KR102363359B1/ko active IP Right Grant
-
2020
- 2020-12-22 JP JP2020212117A patent/JP2021054854A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017389221B2 (en) | 2020-10-08 |
| MA46310B1 (fr) | 2021-04-30 |
| EP3560512A4 (en) | 2020-07-22 |
| CA3048608A1 (en) | 2018-07-05 |
| JP2020512297A (ja) | 2020-04-23 |
| JP6815521B2 (ja) | 2021-01-20 |
| UA124397C2 (uk) | 2021-09-08 |
| CN110198736A (zh) | 2019-09-03 |
| CA3048608C (en) | 2021-11-23 |
| KR20190117462A (ko) | 2019-10-16 |
| PH12019550106A1 (en) | 2020-02-10 |
| NZ755255A (en) | 2021-05-28 |
| WO2018124615A1 (ko) | 2018-07-05 |
| US10940198B2 (en) | 2021-03-09 |
| BR112019013284A2 (pt) | 2019-12-17 |
| MY195766A (en) | 2023-02-10 |
| IL267643B1 (en) | 2023-08-01 |
| MA46310A1 (fr) | 2020-11-30 |
| KR102034234B1 (ko) | 2019-10-18 |
| KR102363359B1 (ko) | 2022-02-16 |
| ZA201904889B (en) | 2020-12-23 |
| MX2019007288A (es) | 2019-10-02 |
| JP2021054854A (ja) | 2021-04-08 |
| IL267643B2 (en) | 2023-12-01 |
| AU2017389221A1 (en) | 2019-08-08 |
| PE20191547A1 (es) | 2019-10-24 |
| KR20180075409A (ko) | 2018-07-04 |
| US20190328868A1 (en) | 2019-10-31 |
| CO2019007795A2 (es) | 2019-08-20 |
| EP3560512A1 (en) | 2019-10-30 |
| CN110198736B (zh) | 2023-12-22 |
| EA038864B1 (ru) | 2021-10-29 |
| IL267643A (ru) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991575A1 (ru) | Вакцинная композиция против опоясывающего герпеса | |
| EA201800108A1 (ru) | Вакцинные композиции для профилактики абровирусных инфекций | |
| EA201691348A1 (ru) | Однофлаконные вакцинные составы | |
| MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| MY194449A (en) | Zika vaccines and immunogenic compositions, and methods of using the same | |
| EA202090049A1 (ru) | Поксвирусные векторы, кодирующие антигены вич, и способы их применения | |
| MX2015010305A (es) | Vacuna de combinacion para virus sincitial respiratorio e influenza. | |
| MX2021010060A (es) | Produccion de virus en huevos aviares. | |
| EA201991377A1 (ru) | Композиции универсальной вакцины против гриппа | |
| BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
| PH12015501716B1 (en) | Anti-mycoplasma spp. subunit vaccine | |
| MX2020005554A (es) | Vacunas y composiciones inmunogenas para zika y metodos para usarlas. | |
| EA201790517A1 (ru) | Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции | |
| MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
| WO2016210083A3 (en) | Inactivated canine influenza vaccines and methods of making and uses thereof | |
| CO2017007057A2 (es) | Vacuna contra la fiebre aftosa | |
| BR112018074910A2 (pt) | composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito | |
| EA201691638A1 (ru) | Новые способы индуцирования иммунного ответа | |
| EA201792512A1 (ru) | Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник | |
| EA201892003A1 (ru) | Лечение атопического дерматита собак | |
| MX2017012389A (es) | Vacuna del virus de la parotiditis recombinante jeryl lynn2. | |
| BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
| AR106501A1 (es) | Adyuvante y composición de vacuna que lo contiene | |
| EA202090236A1 (ru) | Иммуногенные композиции senecavirus a и способы с ними |